UBS initiated coverage on Kadmon Holdings with a new price target
$KDMN
Major Pharmaceuticals
Health Care
UBS initiated coverage of Kadmon Holdings with a rating of Buy and set a new price target of $9.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/14/2021 | $13.00 → $9.50 | Buy → Neutral | Mizuho |
| 9/9/2021 | $10.00 → $9.50 | Buy → Hold | Jefferies |
| 7/19/2021 | $8.00 → $9.00 | Outperform | Oppenheimer |